EGFR and neoplasm: For example, anti-VEGF and EGFR agents could induce tumor vascular normalization, and immunotherapy drugs including anti-PD-1 (programmed death-1) and anti-PD-L1 could remodel the immuno-microenvironment by regulating the immune cells to treat tumors (25).